Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-100 vs MORPHINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing c AMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.
Management of pain in opioid-tolerant patients requiring around-the-clock opioid analgesia for severe chronic pain,Anesthesia (adjunct to general or regional anesthesia),Procedural sedation,Patient-controlled analgesia (PCA),Breakthrough pain management (off-label use)
Moderate to severe acute pain,Severe chronic pain (e.g., cancer-related),Parenteral use for acute pain (e.g., postoperative, trauma),Off-label: dyspnea in palliative care, opioid-induced constipation antagonist in combination products
100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.
5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.
Terminal elimination half-life: 2–4 hours in adults; prolonged in elderly, hepatic impairment, or continuous infusion (due to redistribution).
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (6-8 hours), elderly, and renal impairment (up to 15 hours).
Primarily hepatic via CYP3A4, with minor contribution from CYP3A5. Major metabolites: norfentanyl (inactive), despropionylfentanyl. Approximately 10-25% excreted unchanged in urine.
GFR 30-50 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: reduce dose by 50-75% and extend dosing interval; GFR <10 m L/min: use with caution, consider alternative therapy; not removed by hemodialysis.
GFR 30-50 m L/min: administer 75% of normal dose; GFR 10-29 m L/min: administer 50% of normal dose; GFR <10 m L/min: administer 25% of normal dose.
Risk of respiratory depression, which may be fatal, especially in opioid-naive patients and when used in higher doses or with other CNS depressants. Risk of accidental exposure leading to fatal overdose. Risk of abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected paralytic ileus. Use only in opioid-tolerant patients for outpatient chronic pain management.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal opioid withdrawal syndrome; no structural malformations reported at therapeutic doses.
First trimester: Limited data; no major malformations reported at therapeutic doses. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after birth. High doses near term may cause neonatal respiratory depression.
FENTANYL-100 transdermal patch is indicated only for opioid-tolerant patients with chronic pain requiring around-the-clock analgesia. Apply to non-irritated, non-hairy skin on upper torso or inner forearm; avoid heating pads, saunas, or sun exposure that increase absorption. Monitor for respiratory depression, especially in opioid-naive patients. Patches should be replaced every 72 hours; do not cut or damage the patch. Dispose of used patches by folding adhesive sides together and flushing down toilet.
For opioid-naïve patients, start with immediate-release formulation; use equianalgesic dosing when converting routes (oral to parenteral ratio 3:1 for chronic dosing). Always co-prescribe a bowel regimen (e.g., senna + docusate) due to opioid-induced constipation. Monitor respiratory rate closely, especially in elderly, COPD, or sleep apnea patients. Naloxone is the reversal agent; consider prescribing naloxone for patients on high doses or concomitant benzodiazepines. Morphine is contraindicated in patients with MAOI use within 14 days.
No interactions on record
No interactions on record
Common clinical questions about FENTANYL-100 vs MORPHINE SULFATE, answered by our medical review team.
FENTANYL-100 is a Opioid Agonist that works by Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. MORPHINE SULFATE is a Opioid Agonist that works by Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing c AMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-100 and MORPHINE SULFATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-100 is: 100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.. The standard adult dose of MORPHINE SULFATE is: 5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTANYL-100 and MORPHINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTANYL-100 is classified as Category D/X. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal . MORPHINE SULFATE is classified as Category D/X. First trimester: Limited data; no major malformations reported at therapeutic doses. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily hepatic via glucuronidation (UGT2B7) to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active with greater analgesic potency); minor pathways include N-demethylation to normorphine. Excretion mainly renal.
Primarily hepatic metabolism to inactive metabolites (norfentanyl, etc.); ~75% excreted in urine as metabolites, ~9% in feces, <10% unchanged in urine.
Renal: 90% (primarily as morphine-3-glucuronide and morphine-6-glucuronide, with 10% unchanged); Biliary/Fecal: 7-10%.
~80–85% bound, primarily to albumin and alpha-1-acid glycoprotein.
30-35%, primarily to albumin.
3–8 L/kg (large Vd indicates extensive tissue distribution, especially to fat and muscle).
3-5 L/kg; large Vd indicates extensive tissue distribution, including skeletal muscle and adipose tissue.
Oral: <40% (first-pass metabolism); Buccal: ~50%; Intranasal: 50–90%; Transdermal: ~30–60% (steady state).
Oral: 20-40% (first-pass metabolism); IM/SC: 80-100%; Rectal: 30-50%; Intranasal: 50-60% (variable); IV: 100%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative; monitor for respiratory depression.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use with extreme caution at 25% of normal dose.
Intravenous: 0.5-2 mcg/kg/dose every 2-4 hours; transmucosal: 5-15 mcg/kg for procedural analgesia; transdermal patch: not recommended in children <2 years; in older children, use lowest effective dose based on body weight and opioid tolerance.
0.1-0.2 mg/kg intravenously or intramuscularly every 4 hours as needed; maximum single dose 15 mg.
Start at 25-50% of adult dose; titrate slowly; avoid transdermal patch in opioid-naive elderly; monitor for delirium and respiratory depression; prefer intravenous or buccal routes with careful observation.
Start at 25-50% of the usual adult dose; titrate cautiously; monitor for respiratory depression and constipation.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome (prolonged use in pregnancy); risks with concomitant use of benzodiazepines or other CNS depressants (may cause profound sedation, respiratory depression, coma, death).
Respiratory depression: monitor closely, especially during initiation and dose titration. Abuse and addiction potential: fentanyl is a Schedule II controlled substance. Life-threatening respiratory depression with concurrent use of benzodiazepines or CNS depressants. Serotonin syndrome when coadministered with serotonergic drugs. Adrenal insufficiency. Severe hypotension, including orthostatic hypotension. Risk of seizures in patients with seizure disorders. Avoid use in patients with head injury or increased intracranial pressure. Biliary tract spasm. Use in pregnancy may cause neonatal opioid withdrawal syndrome. Avoid abrupt discontinuation to prevent withdrawal. Must be used only in opioid-tolerant patients for outpatient management.
Risk of respiratory depression (especially in elderly, cachectic, debilitated); risk of opioid-induced hyperalgesia; risk of hypotension (especially in hypovolemic patients); risk of seizures; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; androgen deficiency; severe hypotension; gastrointestinal obstruction; impaired consciousness; head injury; increased intracranial pressure; acute abdominal conditions; biliary tract disease; acute pancreatitis; use in pregnancy (neonatal withdrawal); breastfeeding (withdrawal in infant); use with MAOIs; severe renal or hepatic impairment.
Hypersensitivity to fentanyl or any component of the product, significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, known or suspected gastrointestinal obstruction (including paralytic ileus), concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such therapy.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to morphine or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid or limit alcohol and grapefruit juice as they can potentiate respiratory depression and alter fentanyl metabolism. Maintain adequate hydration and fiber intake to prevent constipation.
Avoid alcohol; may increase CNS depression. Grapefruit juice may theoretically alter morphine metabolism via CYP3A4 inhibition, but clinical significance is minimal; no strict avoidance required. High-fat meals may delay absorption but do not affect overall bioavailability. Maintain adequate fluid and fiber intake to prevent constipation.
Fentanyl is excreted into breast milk in low concentrations; M/P ratio is approximately 0.4. Limited data suggest minimal risk at maternal doses; however, monitor infant for signs of sedation or respiratory depression. Avoid use with breastfeeding for 24 hours after administration due to long half-life.
Morphine is excreted into breast milk. M/P ratio approximately 1.1. In therapeutic doses, amounts are low (<10% of maternal weight-adjusted dose) and unlikely to cause adverse effects in healthy term infants. Caution in preterm infants or those with respiratory compromise.
No specific dose adjustment required for acute pain; however, increased clearance in late pregnancy may necessitate higher doses for chronic pain. Use lowest effective dose for shortest duration to minimize neonatal withdrawal risk.
Increased renal clearance and plasma volume may require higher doses to achieve analgesia. Consider dose titration based on clinical response. Avoid high doses near term to minimize neonatal respiratory depression. Use lowest effective dose for shortest duration.
Apply the patch to clean, dry, hairless skin and press firmly for 30 seconds.,Do not expose the patch to direct heat sources (heating pads, hot tubs, electric blankets).,Keep away from children and pets; used patches must be flushed down toilet.,Do not drink alcohol or take other central nervous system depressants without consulting your doctor.,Report any difficulty breathing, extreme drowsiness, or confusion immediately.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of respiratory depression.,Morphine may cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Constipation is a common side effect; increase fluid and fiber intake, and use a stool softener or laxative as recommended.,Do not stop taking suddenly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely out of reach of children and pets; dispose of unused medication via a take-back program.